Ablynx antibodies news
Ablynx said it plans to separate the chairman and CEO roles at its next shareholder meeting on Nov. 7. The nanobody company said it will name Peter Fellner chairman, while Edwin Moses, currently chairman and CEO, will remain CEO. Ablynx said Belgian law requires having a separate chairman and CEO "unless there are good reasons not to." It said it had combined the roles of chairman and CEO because of Moses' relationships with VCs, but that as VCs are departing the board it is time to appoint an independent chairman.
Stephen Bunting, a managing partner at Abingworth, and Denis Lucquin, a managing partner and chairman of Sofinnova Partners, will resign as directors at Ablynx's November meeting. Ablynx said the VCs would be replaced by independent directors from industry. Abingworth holds a 10% stake in Ablynx, while Sofinnova holds a 7% stake. Nanobodies are therapeutic proteins based on single-domain antibody fragments. ...